Here is a brief summary of items that employers and benefits advisors should be aware of for health plans as we close out 2024 and head into 2025.

While the ruling does not derail the Medicare drug negotiation program, which drugmakers have already agreed to prices for the first 10 drugs selected for the first round, it sends the case back to a lower court for consideration.

The PBMs say out-of-pocket insulin costs have fallen sharply since 2019.

State officials threatened to withhold public money from hospitals, pioneering a strategy that could become a national model.